Products for Research Use Only
RegisterLogin

TSL2109

CAT: 0013-GTR19274609-01Size: 10 mgDry Ice: NoHazardous: No
Product image 1
1 / 1
CAT#:0013-GTR19274609-01Size:10 mg
Selected
24/48H Stock Items & 2 to 6 Weeks non Stock Items.
Quick Request Actions
Description
TSL2109 is an orally active and selective inhibitor of DYRK2 and CDK4/6, with an IC50 value of 22 nM for DYRK2 and over 93% kinase selectivity. In vitro, TSL2109 induces cell cycle arrest and promotes apoptosis (apoptosis) . It effectively overcomes Enzalutamide resistance by inhibiting tumor growth both in vivo and in vitro. Additionally, TSL2109 demonstrates resistance to cyclin-dependent kinase 4/6 (CDK4/6) inhibitors. It shows good safety and is applicable for research in prostate and breast cancer.
CAS Number
2619847-12-8
Smiles
O=C (C1=CN=C (C=C1) NC=2N=CC (F) =C (N2) C=3C=CC=4N=C (SC4C3) N (CC) CC) N5CCN (CC5) C (C) C
Molecular Formula
C28H33FN8OS
Molecular Weight
548.69
Storage Conditions
-20°C
Notes
For research use only.

Popular Products